Inhibition by etomoxir of rat liver carnitine octanoyltransferase is produced through the co-ordinate interaction with two histidine residues.
Rat peroxisomal carnitine octanoyltransferase (COT), which facilitates the transport of medium-chain fatty acids through the peroxisomal membrane, is irreversibly inhibited by the hypoglycaemia-inducing drug etomoxir. To identify the molecular basis of this inhibition, cDNAs encoding full-length wild-type COT, two different variant point mutants and one variant double mutant from rat peroxisomal COT were expressed in Saccharomyces cerevisiae, an organism devoid of endogenous COT activity. The recombinant mutated enzymes showed activity towards both carnitine and decanoyl-CoA in the same range as the wild type. Whereas the wild-type version expressed in yeast was inhibited by etomoxir in an identical manner to COT from rat liver peroxisomes, the activity of the enzyme containing the double mutation H131A/H340A was completely insensitive to etomoxir. Individual point mutations H131A and H340A also drastically reduced sensitivity to etomoxir. Taken together, these results indicate that the two histidine residues, H131 and H340, are the sites responsible for inhibition by etomoxir and that the full inhibitory properties of the drug will be shown only if both histidines are intact at the same time. Our data demonstrate that both etomoxir and malonyl-CoA inhibit COT by interacting with the same sites.
Morillas
M
M
Department of Biochemistry and Molecular Biology, University of Barcelona, School of Pharmacy, Diagonal 643, 08028 Barcelona, Spain.
Clotet
J
J
Rubí
B
B
Serra
D
D
Ariño
J
J
Hegardt
F G
FG
Asins
G
G
D000214:Acyl Coenzyme A / Q000737:chemistry / Q000378:metabolism; D000595:Amino Acid Sequence; D000818:Animals; D001665:Binding Sites; D015153:Blotting, Western; D002331:Carnitine / Q000378:metabolism; D002333:Carnitine Acyltransferases / Q000037:antagonists & inhibitors* / Q000235:genetics; D018076:DNA, Complementary / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004791:Enzyme Inhibitors / Q000494:pharmacology; D004852:Epoxy Compounds / Q000494:pharmacology*; D006639:Histidine / Q000737:chemistry / Q000378:metabolism*; D006801:Humans; D007700:Kinetics; D008099:Liver / Q000201:enzymology*; D008969:Molecular Sequence Data; D016297:Mutagenesis, Site-Directed; D020675:Peroxisomes / Q000201:enzymology; D010957:Plasmids / Q000378:metabolism; D017354:Point Mutation; D011485:Protein Binding; D051381:Rats; D011994:Recombinant Proteins / Q000378:metabolism; D012441:Saccharomyces cerevisiae / Q000378:metabolism; D017386:Sequence Homology, Amino Acid
D000214:Acyl Coenzyme A; D018076:DNA, Complementary; D004791:Enzyme Inhibitors; D004852:Epoxy Compounds; D011994:Recombinant Proteins; C045561:decanoyl-coenzyme A; D006639:Histidine; D002333:Carnitine Acyltransferases; C030162:carnitine octanoyltransferase; C054207:etomoxir; D002331:Carnitine